Delta9-Tetrahydrocannabinol and Cannabidiol as Potential Curative Agents for Cancer: A Critical Examination of the Preclinical Literature
Delta9-Tetrahydrocannabinol and Cannabidiol as Potential Curative Agents for Cancer: A Critical Examination of the Preclinical Literature
复制标题
DOI：
10.1002/cpt.84
复制
发表时间：
2015-06-01
影响因子：
6.7
通讯作者：
Fowler, C. J.
中科院分区：
文献类型：
--
作者：
Fowler, C. J.
在互联网上搜索大麻治疗癌症的关键词，会产生大量声称大麻有这种作用的网站。这些网站向公众免费开放，因此有助于形成舆论。但是Delta(9)-四氢大麻酚(Delta(9)-THC)和大麻二酚(CBD)能治愈癌症吗？在缺乏安全性研究和病例报告以外的临床数据的情况下，临床前数据应根据其预测价值进行评估。使用一种严格的方法，只考虑与临床情况相关的浓度和/或模型，目前的临床前数据尚未提供强有力的证据，表明系统管理的Delta(9)-THC将用于癌症的根治治疗。有更多的人支持在肿瘤内给药更高剂量的Delta(9)-THC。CBD在相关的浓度和模型中产生影响，尽管还需要更多关于其与其他治疗策略结合使用的数据。
An Internet search with search words cannabis cures cancer produce a wealth of sites claiming that cannabis has this effect. These sites are freely accessible to the general public and thus contribute to public opinion. But do delta(9)-tetrahydrocannabinol (Delta(9)-THC) and cannabidiol (CBD) cure cancer? In the absence of clinical data other than a safety study and case reports, preclinical data should be evaluated in terms of its predictive value. Using a strict approach where only concentrations and/or models relevant to the clinical situation are considered, the current preclinical data do not yet provide robust evidence that systemically administered Delta(9)-THC will be useful for the curative treatment of cancer. There is more support for an intratumoral route of administration of higher doses of Delta(9)-THC. CBD produces effects in relevant concentrations and models, although more data are needed concerning its use in conjunction with other treatment strategies.